Idelalisib for treating chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • TA359
  • Published: 
Download guidance (PDF)

1 Guidance

1.1 Idelalisib, in combination with rituximab, is recommended:

  • for untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation or

  • for chronic lymphocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months.

    Idelalisib is recommended only if the company provides the drug with the discount agreed in the simple discount agreement.

1.2 People whose treatment with idelalisib is not recommended in this NICE guidance but was started within the NHS before this guidance was published should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)